Akèy › Kansè san › Maryland › Baltimore
Etid klinik pou Kansè san nan Baltimore, MD
18 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote Baltimore (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Ap rekriteEtid obsèvasyon
- UM Saint Joseph Medical Center, Towson · 8 mi lwen
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Ap rekriteFaz 1 bonè
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Ap rekriteFaz 3
- MedStar Franklin Square Medical Center ( Site 0046), Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0056), Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- ak 2 plis
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 23, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Ap rekriteFaz 1 bonè
- John Hopkins University, Baltimore
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Ap rekriteFaz 1
- Tania Jain, MD, Baltimore
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Ap rekriteFaz 2
- Johns Hopkins Hospital, Baltimore
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Johns Hopkins, Baltimore
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
Ap rekriteFaz 2
- University of Maryland, Baltimore, Baltimore
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Ap rekriteEtid obsèvasyon
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Ap rekriteFaz 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- Johns Hopkins School of Medicine, Baltimore
Ocular Complications From Cancer Therapy - Patient Registry and Biobank
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Stoler Outpatient Cancer Center at the University of Maryland, Baltimore
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Ap rekriteEtid obsèvasyon
- University of Maryland Medical Center, Baltimore
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Johns Hopkins University, Baltimore
Etid Kansè san nan lòt vil
- Houston, TX46 etid
- New York City, NY26 etid
- Boston, MA25 etid
- Washington, DC19 etid
- Seattle, WA18 etid
- Los Angeles, CA17 etid
- Durham, NC16 etid
- Chicago, IL15 etid
- Philadelphia, PA14 etid
- Columbus, OH13 etid
- Edison, NJ13 etid
- Nashville, TN13 etid
Lòt etid nan Baltimore
- Kansè Poumon ki pa ti selil60 etid
- Kansè nan tete47 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Kansè (tout kalite)37 etid
- Kansè pankreyas31 etid
- Kansè kolorektal31 etid
- Kansè Metastatik28 etid
- Obèsite26 etid
- Kansè vejik24 etid
- Ensifizyans kadyak24 etid
- Kansè ovè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.